Novo Nordisk’s CEO, Mike Doustdar, announced a shift in the company’s strategy. He confirmed the Danish drugmaker will now accept more risks in potential mergers and acquisitions (M&A). This new, bold approach focuses entirely on securing the next wave of obesity treatments.
The company’s focus remains on the highly profitable weight-loss market. Novo Nordisk already leads this market with its drug, Wegovy. However, competition is increasing quickly. Rival Pfizer recently beat Novo Nordisk in a bid for the biotech firm Metsera. This loss emphasized the need for quicker, more aggressive deals.
Therefore, the CEO is ready to pay higher prices for promising assets. He wants to bring innovative compounds into the pipeline. Furthermore, the company is not just looking for M&A. Novo Nordisk will also keep investing heavily in its internal research efforts. This dual approach aims to maintain the company’s dominance in the rapidly expanding anti-obesity sector.
